INTRODUCTION
============

Plantar fasciitis (PF) is a common foot disorder involving pain and gait problems \[[@b1-arm-2019-43-6-662],[@b2-arm-2019-43-6-662]\]. The typical pain of PF is located at the medial tubercle of the calcaneus and normally occurs during the first few steps in the morning or after a prolonged non-weight bearing activity. Pain can be reduced after continuing more steps or performing light activities, but it repeatedly returns with prolonged weight-bearing activities \[[@b3-arm-2019-43-6-662],[@b4-arm-2019-43-6-662]\]. Previous studies have reported that heel pain occurs in about 10% of the American population, and 80% of this group was diagnosed with PF \[[@b2-arm-2019-43-6-662],[@b5-arm-2019-43-6-662]\]. In the US healthcare system, more than 2 million patients with PF annually receive assessments and management for their symptoms \[[@b5-arm-2019-43-6-662],[@b6-arm-2019-43-6-662]\]. Diagnosis of PF can be made through the patient history, clinical symptoms, foot questionnaires, and objective assessments such as pain level, palpation, muscle tightness, joint range of motion, or muscle strength \[[@b2-arm-2019-43-6-662],[@b7-arm-2019-43-6-662]\]. In addition, diagnostic imaging may be used to exclude other causes of pain such as heel spurs or tissue inflammation \[[@b7-arm-2019-43-6-662],[@b8-arm-2019-43-6-662]\].

The main problem in PF is heel pain during weightbearing activities, especially walking, which is the most essential function for daily living \[[@b9-arm-2019-43-6-662]\]. Walking problems in patients may result in restrictions in function, working, social participation, and quality of life (QoL) \[[@b2-arm-2019-43-6-662]\]. Patients with PF who have painful episodes at the heel commonly avoid weight bearing on the symptomatic foot and are at risk for developing antalgic gait \[[@b3-arm-2019-43-6-662]\]. Patients with PF tend to walk more slowly than healthy individuals in order to avoid or reduce pain \[[@b10-arm-2019-43-6-662]\]. They show significant decreases in cadence, gait speed, stride length, and increases in stride time \[[@b11-arm-2019-43-6-662],[@b12-arm-2019-43-6-662]\]. In addition, the adaptation mechanism of antalgic gait may present in individuals in the chronic phase or a non-painful episode of PF \[[@b3-arm-2019-43-6-662],[@b10-arm-2019-43-6-662]\]. As previously mentioned, foot pain from PF can reduce foot function and walking capacity, thus leading to decreased general health-related QoL \[[@b9-arm-2019-43-6-662]\]. The lack of walking or weight-bearing activities could result in the loss of muscle strength and muscle flexibility, development of an inactive lifestyle, and increased body weight \[[@b13-arm-2019-43-6-662]\]. Therefore, PF treatment is necessary to preserve QoL and prevent other potential problems \[[@b13-arm-2019-43-6-662]\].

Several treatment techniques have been conducted for patients with PF \[[@b1-arm-2019-43-6-662],[@b3-arm-2019-43-6-662],[@b4-arm-2019-43-6-662],[@b6-arm-2019-43-6-662]\]. Generally, these patients start with non-surgical or conservative treatment. If this treatment cannot improve the symptoms after 6--12 months, surgical treatment will be considered \[[@b3-arm-2019-43-6-662]\]. Conservative treatments for PF usually include rest, anti-inflammatory drugs, shoe inserts, shoe wear modification, stretching exercises, and physical therapy. Examples of physical therapy are massage, mobilization, therapeutic ultrasound, and taping. However, there is controversy about the treatment benefits and there is insufficient evidence about their efficacy \[[@b1-arm-2019-43-6-662],[@b2-arm-2019-43-6-662],[@b4-arm-2019-43-6-662],[@b14-arm-2019-43-6-662]\]. Among several conservative treatments, only gastrocnemius muscle and plantar fascia stretching were shown to have moderate treatment effects; they are often used in the treatment programs for patients with PF \[[@b1-arm-2019-43-6-662],[@b4-arm-2019-43-6-662]\]. In 2006, Digiovanni et al. \[[@b15-arm-2019-43-6-662]\] reported that specific stretches of the plantar fascia for 8 weeks had the long-term benefit of reducing pain and function limitations, with a high rate of patient satisfaction.

Even though PF has several risk factors, an abnormal biomechanical structure is considered to play an important role. Abnormalities include tightness in the Achilles tendon and plantar fascia and reduced foot and ankle muscle strength \[[@b13-arm-2019-43-6-662],[@b16-arm-2019-43-6-662]\]. Patients with PF often also have myofascial restrictions and muscle stiffness or tightness in the gastro-soleus complex and plantar fascia \[[@b17-arm-2019-43-6-662],[@b18-arm-2019-43-6-662]\]. In 2015, Sullivan et al. \[[@b19-arm-2019-43-6-662]\] identified musculoskeletal factors in patients with PF compared to normal healthy people, and they found weakness in various muscles such as ankle evertors (peroneus brevis and longus) and toe flexors (flexor hallucis longus and brevis, flexor digitorum longus and brevis) \[[@b19-arm-2019-43-6-662]\]. In addition, weakness of the tibialis posterior muscle was also reported in previous studies \[[@b4-arm-2019-43-6-662],[@b20-arm-2019-43-6-662]\]. Weakness of the intrinsic and extrinsic muscles of the foot may result in the recurrent symptoms of PF due to improper functioning of the muscle and joint positioning during walking \[[@b4-arm-2019-43-6-662],[@b13-arm-2019-43-6-662],[@b19-arm-2019-43-6-662]\]. Rathleff et al. \[[@b21-arm-2019-43-6-662]\] in 2014 reported that daily heel-raising exercises have superior effectiveness at 3 months than plantar-specific stretching. However, these exercises showed no difference in foot function at 1, 2, 6, or 12 months after this intervention.

The aforementioned exercise programs have an impact on PF recovery because they increase muscle strength and reduce muscle tightness. There was a limited number of studies comparing the effect of strengthening and stretching exercises; hence, it is still uncertain which exercises will improve more PF symptoms. Therefore, this study aimed to investigate the effects of strengthening and stretching exercise programs combined with a physical therapy intervention on pain intensity and temporospatial gait parameters in patients with PF. The hypothesis of this study was that the strengthening and stretching exercise programs may have different effects on reducing pain and improving gait performance.

MATERIALS AND METHODS
=====================

A double-blind, randomized controlled trial was used in the study. The study was performed from July 2017 to February 2019 at the Physical Therapy Center, Faculty of Physical Therapy, Mahidol University, Thailand. The study protocol was approved by the Institutional Review Board of Mahidol University (No. MU-CIRB 2016/182.0211). Before participating in the study, the participants received explanations about the procedures and signed consent forms.

Participants
------------

Patients with unilateral or bilateral PF were screened and recruited through printed and digital media. Participants were recruited if they met the following criteria: heel pain for more than 1 month; history of heel pain during the first few steps in the morning or after prolonged non-weight bearing activities \[[@b1-arm-2019-43-6-662],[@b22-arm-2019-43-6-662]\]; pain with tenderness on palpation at the medial tubercle of calcaneus; and thickness of the plantar fascia greater than 4.0 mm, assessed by a portable digital ultrasound diagnosis imaging system (D-6600; Mindray Bio-Medical Electronics Co. Ltd., Zhenzhen, China) \[[@b22-arm-2019-43-6-662],[@b23-arm-2019-43-6-662]\]. Participants were excluded if they had a history of back or lower limb surgery, fracture or trauma within 6 months, leg length discrepancy greater than 1 cm, corticosteroid injections within 6 months, pregnancy, and inability to perform the exercise program. In addition, participants were excluded if they were receiving any other intervention or performing other foot-specific exercises during the study. Furthermore, if the participants had Achilles tendinopathy, acute ankle sprains, tarsal tunnel syndrome, or patellofemoral syndrome during physical examinations, they were excluded. If palpation, pain in the center of calcaneus, and ultrasound indicated calcaneal spurs and heel pad syndrome, the participants were excluded. Patients with systematic diseases such as rheumatoid arthritis, fibromyalgia or neuropathy, neurological diseases, and diseases of the central or peripheral nervous system were excluded if they exhibited symmetrical pain and inflammation, general numbness, or a history of symptoms. These criteria were screened by a physical therapist with an experience of more than 5 years in the musculoskeletal field. A summary of the flowchart diagram is illustrated in [Fig. 1](#f1-arm-2019-43-6-662){ref-type="fig"}.

Among the 102 eligible participants aged between 20 and 80 years, 18 were excluded according to the recruitment criteria due to Achilles tendinitis (n=3), acute ankle sprain (n=2), heel pad syndrome (n=4), pain in lower extremity (n=5), or inability to follow the research timeline (n=4). Therefore, 84 patients with PF participated in this study, and there were no dropouts. A stratified randomization table according to age (less or more than 50 years) and pain score (less or more than 5 out of 10 scores) was used to randomize the participants into the strengthening (n=42) or stretching (n=42) groups.

Evaluation
----------

The researcher evaluated all participants five times, at the baseline, intermediate of the intervention, end of the intervention, and 1 and 2 month follow-ups after the end of the intervention. At the baseline, the demographic data collected by questionnaire included age, height, weight, PF characteristic, PF side, lower limb dominance, pain characteristic, and underlying diseases.

The participants were asked about their worst pain during the current day (worst pain) and their pain when taking the first few steps in the morning (morning pain) using the 10-cm visual analogue scale (VAS). The left and right ends of the line demonstrate 'no pain' as the '0 score' and the 'worst pain ever' with the '10 scores', respectively.

The temporospatial parameters of the patients were evaluated on a 3-m force distribution platform (The Zebris FDM-System-Gait Analysis; Zebris Medical GmbH, Isny, Germany) with a sampling frequency of 100 Hz and synchronized with a video camera (SC-1 SYNCCam; Zebris Medical GmbH). The video camera was placed at the end of the platform. The participants stood at the edge of the platform and were asked to walk barefoot at a comfortable speed to the other end of the platform. Data were collected for 3 trials, and the averaged data were used in the comparisons. The temporospatial gait parameters consisted of cadence (step/min), gait speed (m/s), stride time (s), stride length (m), step width (m), and double support time (%).

Intervention protocol
---------------------

Both groups received the same conservative physical therapy intervention by the first physical therapist. This intervention consisted of therapeutic ultrasound and manual therapy eight times (two times per week over 4 weeks) followed by the assigned exercise program. The second and the third physical therapists instructed the participants to perform the strengthening and stretching exercises and reminded them to do the home-based exercise program three times per day. These two physical therapists only knew the details of their assigned exercise program; hence, they were blinded from the other exercise program. In addition, the participants also were blinded from the other exercise group. After the end of the intervention, participants continued their exercise programs at home for 2 months. All participants received illustrated instruction sheets with the details of the daily exercise program and its progression protocol. To monitor their compliance, we asked them to record their exercises in a logbook.

Therapeutic ultrasound (Sonopuls 492; Enraf-Nonius, Rotterdam, The Netherlands) with a 50% pulse mode at a frequency of 1.0 MHz and intensity of 1.5 W/cm^2^ was applied to the participants for 5 minutes with a slow circular movable technique on the most tender or painful area of the heel \[[@b24-arm-2019-43-6-662]\]. After finishing therapeutic ultrasound, manual therapy, plantar fascia stretching, and tissue mobilization \[[@b25-arm-2019-43-6-662]\], anteroposterior (AP) mobilization on the talocrural joint \[[@b25-arm-2019-43-6-662],[@b26-arm-2019-43-6-662]\] and eversion-inversion mobilization on the subtalar joint \[[@b26-arm-2019-43-6-662]\] were performed.

The strengthening exercise program consisted of a toe curl exercise, ankle evertor exercise, ankle invertor exercise, and heel raise exercise \[[@b21-arm-2019-43-6-662],[@b26-arm-2019-43-6-662]\]. The starting level of each exercise was selected individually by the physical therapist, evaluating participant performance. The exercise progression also based on the individual achievement of the previous level for each exercise. The toe curl exercise placed a kilogram sandbag on a towel for each additional level of progression. For the ankle evertor and invertor exercise, a harder TheraBand resistance band was placed at each level. The heel raise exercise progressed by its starting position; both feet with hand support, both feet without hand support, single foot with hand support, and single foot without hand support.

The stretching exercise program consisted of stretching the gastrocnemius muscle, soleus muscle, and plantar fascia \[[@b26-arm-2019-43-6-662],[@b27-arm-2019-43-6-662]\]. A summary of the manual physical therapy interventions, strengthening exercises, and stretching exercise programs is presented in [Table 1](#t1-arm-2019-43-6-662){ref-type="table"}.

Statistical analysis
--------------------

SPSS version 25 (IBM SPSS, Armonk, NY, USA) was used for statistical analysis. The statistical significance was estimated at p\<0.05. The Kolmogorov-Smirnov goodness of fit test was used to test the data distribution; it showed a normal distribution.

The outcome measures were analyzed by the two-way repeated measure for ANOVA to investigate the main effects of time (at the baseline, intermediate of intervention, end of the intervention, first and second month follow-ups), main effects of the groups (strengthening and stretching), and interaction effects of time by group on the testing parameters. In addition, the Bonferroni posthoc analysis was used to find the pair of differences, and the independent sample t-test was used to find the differences between groups at each of the assessment times.

Sample size calculation
-----------------------

The sample size for this study was calculated based on the previous study \[[@b28-arm-2019-43-6-662]\]. The study investigated the effectiveness of low-level laser therapy to the improvement of gait speed in patients with PF (n=49) and showed that the average and standard deviation of gait speed in the experimental and control groups were 1.15±0.26 and 1.25±0.26 m/s, respectively. Using the G\*Power program version 3.1.9.2 with the function of the t-test and setting the alpha error to 0.05 and power to 0.80, the estimated total sample number was 55 participants. Thus, the 84 samples that the present study collected were sufficient.

RESULTS
=======

Demographic data of the participants in both groups are shown in [Table 2](#t2-arm-2019-43-6-662){ref-type="table"}. There were no significant differences (p\>0.05) in age, gender, weight, height, worst pain, morning pain, PF side, PF characteristic, pain characteristic, and underlying disease between groups at the baseline.

There were significant effects of time on the worst pain (F~(3.283,\ 269.201)~=65.661, p\<0.001), morning pain (F~(2.812,\ 230.624)~=87.421, p\<0.001), cadence (F~(3.066,\ 251.398)~=7.663, p\<0.001), stride length (F~(2.986,\ 244.848)~=9.239, p\<0.001), stride time (F(2.872, 235.543)=8.687, p\<0.001), total double support (F~(3.607,\ 295.757)~=3.601, p=0.009), and gait speed (F~(2.862,\ 234.653)~=14.411, p\<0.001), but no significant effect of time on the step width (F~(4,\ 298.537)~=1.348, p=0.252). There were no significant effects on the group for worst pain (F~(1,\ 82)~=0.128, p=0.721), morning pain (F~(1,\ 82)~=0.276, p=0.601), cadence (F~(1,\ 82)~=0.088, p=0.768), step width (F~(1,\ 82)~=0.001, p=0.975), stride length (F~(1,\ 82)~=0.045, p=0.832), stride time (F~(1,\ 82)~=0.187, p=0.666), total double support (F~(1,\ 82)~=0.571, p=0.452), and gait speed (F~(1,\ 82)~=0.092, p=0.763). There were no significant interaction effects on the time and group for worst pain (F~(3.283,\ 269.201)~=0.313, p=0.833), morning pain (F~(2.812,\ 230.624)~=1.315, p=0.271), cadence (F~(3.066,\ 251.398)~=1.378, p=0.250), step width (F~(4,\ 298.537)~=0.611, p=0.655), stride length (F~(2.986,\ 0.013)~=1.924, p=0.127), stride time (F(2.872, 235.543)=1.407, p=0.242), total double support (F~(3.607,\ 295.757)~=0.851, p=0.484), and gait speed (F~(2.862,\ 234.653)~=1.325, p=0.268).

[Table 3](#t3-arm-2019-43-6-662){ref-type="table"} shows intra- and inter-group comparisons for the pain intensity and the temporospatial gait parameters. [Fig. 2](#f2-arm-2019-43-6-662){ref-type="fig"} shows the changes in pain intensity, and [Fig. 3](#f3-arm-2019-43-6-662){ref-type="fig"} shows the changes in temporospatial gait parameters for both groups within 3 months. [Tables 4](#t4-arm-2019-43-6-662){ref-type="table"} and [5](#t5-arm-2019-43-6-662){ref-type="table"} show pairwise comparisons of the pain intensity and the temporospatial gait parameters (except for the step width, which showed no difference) in the strengthening and stretching groups.

In the strengthening group, there were significant differences in the worst pain between the baseline and intermediate of the intervention (p\<0.001), the baseline and end of the intervention (p\<0.001), the baseline and first month follow-up (p\<0.001), the baseline and second month follow-up (p\<0.001), the intermediate of the intervention and first month follow-up (p=0.002), the intermediate intervention and second month follow-up (p\<0.001), and the end of the intervention and second month follow-up (p=0.005). For morning pain, significant differences were found between the baseline and intermediate of the intervention (p\<0.001), the baseline and end of the intervention (p\<0.001), the baseline and first month follow-up (p\<0.001), the baseline and second month follow-up (p\<0.001), the intermediate and end of the intervention (p=0.028), the intermediate of the intervention and first month follow-up (p\<0.001), the intermediate of the intervention and second month followup (p\<0.001), the end of the intervention and second month follow-up (p\<0.001), and then first and second month follow-ups (p=0.002). For cadence, a significant difference was found between the intermediate and end of the intervention (p=0.031). For stride time, significant differences were found between the intermediate of the intervention and first month follow-up (p=0.018), and the intermediate of the intervention and second month follow-up (p=0.020). In addition, no significant differences (p\>0.05) of stride length, total double support, and gait speed among the times of assessment were found.

In the stretching group, there were significant differences in the worst pain baseline and intermediate of intervention (p=0.002), the baseline and end of the intervention (p\<0.001), the baseline and first month followup (p\<0.001), the baseline and second month followup (p\<0.001), the intermediate of intervention and first month follow-up (p=0.004), the intermediate of intervention and second month follow-up (p\<0.001), and the end of the intervention and second month followup (p=0.005). For morning pain, significant differences were found between the baseline and intermediate of the intervention (p=0.011), the baseline and end of the intervention (p\<0.001), the baseline and first month followup (p\<0.001), the baseline and second month follow-up (p\<0.001), the intermediate and end of the intervention (p=0.001), the intermediate of the intervention and first month follow-up (p\<0.001), the intermediate of the intervention and second month follow-up (p\<0.001), the end of the intervention and first month follow-up (p=0.043), and the end of the intervention and second month follow-up (p=0.016). For cadence, significant differences were found between the baseline and first month followup (p=0.012) and between the baseline and second month follow-up (p=0.045). For stride length, significant differences were found between the baseline and intermediate of the intervention (p=0.047), the baseline and first month follow-up (p=0.002), and the intermediate of the intervention and second month follow-up (p=0.001). For stride time, significant differences were found between the baseline and first month follow-up (p=0.008) and between the intermediate of the intervention and second month follow-up (p=0.043). For double support time, a significant difference was found between the baseline and second month follow-up (p=0.030). For gait speed, significant differences were found between the baseline and intermediate of the intervention (p=0.010), the baseline and first month follow-up (p=0.001), the baseline and second month follow-up (p\<0.001), and the end of intervention and second month follow-up (p=0.003).

DISCUSSION
==========

In this study, patients with PF were randomly allocated to two groups to receive physical therapy treatment with the strengthening or stretching exercise programs for 12 weeks. The results showed that both groups attained similar enhancements in the reduction of pain and improvement of gait parameters. The worst pain and morning pain similarly decreased in both groups. This result was similar to the previous findings that showed the reduction of pain after patients with PF received stretching and strengthening exercises \[[@b27-arm-2019-43-6-662],[@b29-arm-2019-43-6-662],[@b30-arm-2019-43-6-662]\]. When compared to the baseline, the worst pain and morning pain started to show a significant reduction at the intermediate of the intervention and continued to reduce until the end of 3 months. Although the findings did not show a statistically significant difference between groups, the strengthening group had a slight decrease in morning pain in the first month, more than in the stretching group. The stretching group tended to have a slight increase in stride length at the 3-month follow-up, more than in the strengthening group. The effect of strengthening and stretching exercises on testing outcomes demonstrated in this study may suggest whether therapists select either strengthening or stretching exercise programs for recovering from pain and improving gait function in patients with PF. The selection may be decided based on the clinical characteristics of the patients, the availability of the instrument, and the proper location for each exercise protocol.

From our study, the change of morning pain in the first month of the strengthening group was 2.96 cm and that of the stretching was 2.29 cm. A previous study reported that the minimal clinically important difference (MCID) of the 10-cm VAS pain score was 3 cm \[[@b31-arm-2019-43-6-662]\] and the minimal important difference (MID) of 10-cm VAS pain was 0.8 cm for the average pain and 1.9 cm for the first step (or morning) pain \[[@b32-arm-2019-43-6-662]\], although the comparison between groups was not statistically different. But it may be implied that the level of morning pain was decreased with the clinical effects for the strengthening group more than that of the stretching group.

The present study found that both groups could improve their temporospatial parameters with no difference between the two exercise programs. The strengthening group showed improvements in cadence at the first month follow-up and in stride time at the second month follow-up. The stretching group showed improvements in cadence and stride time at the first month followup, improved double support time at the second month follow-up, and improved stride length and gait speed at the intermediate of the intervention. From the previous study, the recommended criteria for meaningful change in stride length was 0.005 m \[[@b33-arm-2019-43-6-662]\]. In our results, the changes of stride length in the strengthening and stretching were 0.02 and 0.05 m, respectively. This may identify the important changes over time for both exercise programs in the clinic. For the overall change in temporospatial parameters, both groups showed improvements in the same direction. We found that the restoration of gait parameters returned to the normal values \[[@b34-arm-2019-43-6-662]\]. At the end of the study, cadence, gait speed, and stride length were increased, while stride time and double support time were decreased. The step width was the only parameter that did not change, which could be explained by the relationship between pain and gait performance. When the pain decreased, patients with PF were able to put more weight on the symptomatic foot; therefore, the single support time was increased and the total double support time was decreased. In addition, pain reduction may reduce stride time and result in increased gait speed and cadence.

The intrinsic and extrinsic foot muscles play an important role in maintaining the arches of the foot while walking \[[@b30-arm-2019-43-6-662]\]. The strengthening exercise program for these muscles was expected to have better improvements in pain and gait parameters than the stretching exercise program \[[@b19-arm-2019-43-6-662],[@b35-arm-2019-43-6-662]\]. However, the present study found the same effect from both programs on pain and gait. In patients with PF, there were reports about the weakness of the ankle dorsiflexors \[[@b19-arm-2019-43-6-662],[@b36-arm-2019-43-6-662]\] and limitations of the ankle dorsiflexion range of motion or tightness of the ankle plantar flexors \[[@b37-arm-2019-43-6-662],[@b38-arm-2019-43-6-662]\]. Any improvement may have been due to the major benefits of stretching exercise in the first month of intervention, whereas the strengthening exercises created long-term benefits at the 2-month followup. Moreover, the improvements in both groups may have occurred due to the increased ankle dorsiflexion range of motion obtained through the stretching exercises for the calf muscles and Achilles tendon \[[@b21-arm-2019-43-6-662]\]. In the strengthening exercises, an additional benefit was gained from the heel raise exercise, which required the utilization of forth-back muscle work to control up and down body movement while bearing body weight, improving the strength of both the ankle dorsiflexors and the plantar flexors. In addition, it also increased the ankle dorsiflexion range of motion and stretched the calf and Achilles tendons as the patients lowered down.

Further studies may examine others clinical characteristic such as the calf muscle, Achilles tendon, and plantar fascia tightness, or ankle and toe muscle strength. These clinical characteristics may affect the effectiveness of the exercise program; hence, they should be controlled to reduce the effect of these confounding factors.

The limitations of this study include the following; first, there was not a non-intervention group in this study; hence, it cannot quantify the spontaneous progression of the symptoms. Second, the study did not differentiate between bilateral or unilateral types of PF. The findings may be different due to the adaptation to these conditions, in particular, the temporospatial parameters. However, the baseline characteristics of the participants were not different because of the random allocation and control. Thirdly, confounding factors may have occurred during the study because we did not note the patients' behaviors such as changes in activity or lifestyle, shoes, or weight. However, we asked about other interventions, exercises, and drug usage at the end of the study. Furthermore, we requested that patients avoid taking painkiller or antiinflammatory drugs, performing other foot exercises, and walking on uneven or hard surfaces. We also encouraged the patients to wear proper shoes with firm insoles and to avoid high heels. Lastly, to obtain insightful details, a long-term follow-up on these patients should occur in the future.

In conclusion, both the strengthening and stretching exercise programs could reduce the pain and improve gait performance in patients with PF within 3 months. There were no differences in the testing parameters between the strengthening and stretching groups.
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![The temporospatial gait parameters over 3 months in the strengthening (STT) and stretching (STC) groups: (A) cadence, (B) step width, (C) stride length, (D) stride time, (E) total double support, and (F) velocity.](arm-2019-43-6-662f3){#f3-arm-2019-43-6-662}

###### 

Manual physical therapy, strengthening exercise, and stretching exercise programs

                                           Intervention                                                              Participant position                                                                                                                                                                          Protocol                                                                                                                                                                         Progression                                                              Intensity                                                                Duration (min)
  ---------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------ ----------------
  Manual physical therapy (mobilization)   Plantar fascia stretching and tissue                                      Prone lying with ankle over the edge                                                                                                                                                          Fixed calcaneus with all toes in full dorsiflexion, then press thumb and glide along the PF (proximal to distal)                                                                 None                                                                     Pressure depends on patient tolerance                                    5
  Talocrural joint AP                      Supine lying with ankle over the edge                                     Stabilize lateral and media malleolus and another hand grasps over talus, then apply force in AP direction                                                                                    None                                                                                                                                                                             Mobilization grade III+ to III++ with large amplitude oscillation        1.5                                                                      
  Subtalar joint eversioninversion         Prone lying with knee and ankle bend at 90º                               Both hands grasp around calcaneus move lower leg close and away while keeping the foot parallel to the floor                                                                                  None                                                                                                                                                                                                                                                      1.5                                                                      
  Strengthening exercise program           Toe curl                                                                  Sitting and place PF foot over towel on the floor                                                                                                                                             Flex all toes to curl the towel toward body (1 second), then extend back (1 second) to starting position                                                                         Weight placed on towel by increased 1 kg for each level                  15 repetitions for 3 sets                                                2
  Ankle evertor                            Long sitting with both legs slightly abduction                            Tie resistive band as a loop around both feet, then evert as far as possible for 1 second (other side stays as the stabilizer), and back to starting position for 1 second                    Harder resistive band will be replaced for next level                                                                                                                            10 repetitions for 3 sets                                                2                                                                        
  Ankle invertor                           Long sitting with both legs slightly abduction                            Tie resistive band as a loop around symptomatic foot and stable pole, then start invert as far as possible for 1 second (do not rotate the leg), and back to starting position for 1 second   Harder resistive band will be replaced for next level                                                                                                                            10 repetitions for 3 sets                                                2                                                                        
  Heel raise                               Standing on the first step of stairway with towel roll place under toes   Going up 3 seconds, pause at the top for 2 seconds, and coming down 3 seconds, then back to starting position                                                                                 4 levels; both legs with hands support, both legs with no hand support, single leg with hand support, and single leg with no hand support                                        10 repetitions for 3 sets                                                3                                                                        
  Stretching exercise program              Gastrocnemius                                                             Step standing and facing the wall                                                                                                                                                             PF foot placed behind with leg straight, then bend front knee and lean body forward to the wall until feel tight of the calf or Achilles tendon (both heel touching the floor)   None                                                                     3 repetitions with 30 seconds and rest 10 seconds between each stretch   2
  Soleus                                   Step standing and facing the wall                                         PF foot placed behind, then bend both knee and lean body forward to the wall until feel tight of the calf or Achilles tendon (both heels touch the floor)                                     None                                                                                                                                                                             3 repetitions with 30 seconds and rest 10 seconds between each stretch   2                                                                        
  PF                                       Sitting on the chair                                                      Crossing PF leg over contralateral leg, grasps around calcaneus and another hand grasps under the toes, then pull the toes backward to the shin until feeling tight in the sole               None                                                                                                                                                                             3 repetitions with 30 seconds and rest 10 seconds between each stretch   2                                                                        

AP, anteroposterior; PF, plantar fasciitis.

###### 

Demographic data of the participants in strengthening and stretching groups

  Characteristic                                                                   Strengthening group (n=42)   Stretching group (n=42)   p-value
  -------------------------------------------------------------------------------- ---------------------------- ------------------------- ---------
  Age (yr)^[a)](#tfn1-arm-2019-43-6-662){ref-type="table-fn"}^                     51.95±10.10                  52.86±9.84                0.679
  Gender^[b)](#tfn2-arm-2019-43-6-662){ref-type="table-fn"}^                                                                              0.321
   Male                                                                            13 (31)                      9 (21.4)                  
   Female                                                                          29 (69)                      33 (78.6)                 
  Weight (kg)^[a)](#tfn1-arm-2019-43-6-662){ref-type="table-fn"}^                  65.66±11.26                  65.14±12.52               0.844
  Height (cm)^[a)](#tfn1-arm-2019-43-6-662){ref-type="table-fn"}^                  161.13±9.18                  159.45±8.13               0.380
  Pain intensity (VAS score)^[a)](#tfn1-arm-2019-43-6-662){ref-type="table-fn"}^                                                          
   Pain at worst                                                                   5.96±2.30                    5.74±2.30                 0.660
   Pain at morning                                                                 5.86±2.51                    5.04±2.35                 0.128
  PF side^[b)](#tfn2-arm-2019-43-6-662){ref-type="table-fn"}^                                                                             1.000
   Right                                                                           25 (59.5)                    25 (59.5)                 
   Left                                                                            17 (40.5)                    17 (40.5)                 
  PF characteristic^[b)](#tfn2-arm-2019-43-6-662){ref-type="table-fn"}^                                                                   1.000
   Unilateral                                                                      23 (54.8)                    23 (54.8)                 
   Bilateral                                                                       19 (45.2)                    19 (45.2)                 
  Pain characteristic^[b)](#tfn2-arm-2019-43-6-662){ref-type="table-fn"}^                                                                 
   Few step in the morning                                                         42 (100)                     40 (95.24)                0.152
   After prolong sitting                                                           23 (54.76)                   29 (69.05)                0.178
   After prolong standing or walking                                               20 (47.62)                   17 (40.48)                0.510
   During running                                                                  12 (28.57)                   12 (28.57)                1.000
  Underlying disease^[b)](#tfn2-arm-2019-43-6-662){ref-type="table-fn"}^                                                                  
   None                                                                            18 (42.86)                   25 (59.52)                0.127
   Hypertension                                                                    11 (26.19)                   9 (21.43)                 0.608
   Diabetes mellitus                                                               2 (4.76)                     1 (2.38)                  0.557
   Hyperlipidemia                                                                  5 (11.90)                    2 (4.76)                  0.236
   Hyperthyroid                                                                    3 (7.14)                     1 (2.38)                  0.306
   Allergy                                                                         1 (2.38)                     3 (7.14)                  0.306

Values are presented as mean±standard deviation or number (%).

VAS, visual analogue scale (10 cm); PF, plantar fasciitis.

Comparisons of the continuous data between two groups by the independent sample t-test with significant tested at p\<0.05.

Comparisons of the nominal data between two groups by the chi-square test with significant tested at p\<0.05.

###### 

Intra- and inter-group comparisons for the pain intensity and the temporospatial gait parameters

  Parameter                                                      Baseline       Intermediate of intervention   End of intervention   1st month follow-up   2nd month follow-up   df      df~error~   F        p-value^[a)](#tfn3-arm-2019-43-6-662){ref-type="table-fn"}^
  -------------------------------------------------------------- -------------- ------------------------------ --------------------- --------------------- --------------------- ------- ----------- -------- -------------------------------------------------------------
  Worst pain (score)                                                                                                                                                                                          
   Strengthening group                                           5.96±2.30      3.91±2.38                      3.09±2.25             2.52±2.55             1.73±2.16             4       164         36.280   \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   Stretching group                                              5.74±2.30      4.08±2.29                      3.34±2.47             2.69±2.55             2.05±2.24             3.133   128.462     29.527   \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       0.441          0.341                          0.485                 0.317                 0.659                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.660          0.734                          0.629                 0.752                 0.512                                              
  Morning pain (score)                                                                                                                                                                                        
   Strengthening group                                           5.86±2.51      3.70±2.28                      2.90±2.46             2.25±2.51             1.30±1.54             2.812   115.290     58.565   \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   Stretching group                                              5.04±2.35      3.63±2.54                      2.75±2.52             1.98±2.24             1.52±2.12             2.675   109.672     32.411   \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       1.538          0.140                          0.263                 0.523                 0.565                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.128          0.889                          0.793                 0.602                 0.574                                              
  Cadence (step/min)                                                                                                                                                                                          
   Strengthening group                                           103.16±7.75    102.85±8.54                    104.03±8.42           104.72±8.45           105.50±8.47           2.905   119.114     3.741    0.014^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   Stretching group                                              101.37±10.44   103.70±9.82                    103.46±10.42          104.16±9.35           104.81±9.49           2.764   113.330     5.301    0.002^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       0.893          0.423                          0.279                 0.285                 0.350                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.374          0.674                          0.781                 0.778                 0.727                                              
  Step width (m)                                                                                                                                                                                              
   Strengthening group                                           0.11±0.03      0.11±0.03                      0.11±0.03             0.11±0.03             0.11±0.03             3.358   137.697     0.754    0.536
   Stretching group                                              0.11±0.04      0.11±0.04                      0.11±0.04             0.11±0.04             0.11±0.04             4       164         1.187    0.319
   t value                                                       0.118          0.176                          0.278                 0.234                 0.123                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.907          0.861                          0.782                 0.816                 0.902                                              
  Stride length (m)                                                                                                                                                                                           
   Strengthening group                                           1.05±0.11      1.06±0.10                      1.05±0.10             1.07±0.09             1.07±0.10             3.059   125.427     1.648    0.181
   Stretching group                                              1.03±0.10      1.06±0.10                      1.05±0.10             1.07±0.11             1.08±0.10             4       114.691     9.635    \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       0.864          0.293                          0.522                 0.098                 0.585                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.390          0.770                          0.603                 0.922                 0.560                                              
  Stride time (s)                                                                                                                                                                                             
   Strengthening group                                           1.17±0.09      1.17±0.10                      1.15±0.10             1.15±0.10             1.14±0.10             2.846   116.692     4.248    0.008^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   Stretching group                                              1.19±0.13      1.16±0.12                      1.17±0.13             1.16±0.11             1.15±0.11             2.546   104.393     5.755    0.002^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       0.971          0.299                          0.530                 0.411                 0.377                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.334          0.766                          0.598                 0.682                 0.707                                              
  Total double support (%)                                                                                                                                                                                    
   Strengthening group                                           30.75±3.76     30.66±3.63                     30.41±3.90            30.68±3.96            30.13±3.71            3.264   133.840     1.343    0.262
   Stretching group                                              31.69±3.52     30.79±3.61                     31.18±3.72            31.23±3.95            30.55±3.24            4       164         2.856    0.025^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       1.187          0.167                          0.955                 0.635                 0.544                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.239          0.868                          0.342                 0.527                 0.588                                              
  Gait speed (m/s)                                                                                                                                                                                            
   Strengthening group                                           0.90±0.11      0.91±0.12                      0.92±0.12             0.93±0.12             0.94±0.12             3.264   133.840     1.343    0.262
   Stretching group                                              0.87±0.13      0.91±0.13                      0.91±0.13             0.93±0.13             0.94±0.13             2.680   109.868     11.772   \<0.001^[\*](#tfn5-arm-2019-43-6-662){ref-type="table-fn"}^
   t value                                                       1.071          0.176                          0.507                 0.171                 0.141                                              
   p-value^[b)](#tfn4-arm-2019-43-6-662){ref-type="table-fn"}^   0.287          0.861                          0.641                 0.864                 0.888                                              

Values are presented as mean±standard deviation.

VAS, visual analogue scale (10 cm).

Based on the Repeated measure ANOVA or intra-group (Time effect).

Based on the independent sample t-test or inter-group (Group effect).

p\<0.05.

###### 

Pairwise comparison for the strengthening group (p-value)

  Parameter                       Baseline                                                      Intermediate of intervention                                  End of intervention                                           1st month follow-up                                         2nd month follow-up
  ------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- ---------------------
  Worst pain (VAS score)                                                                                                                                                                                                                                                                
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   N/A                                                                                                                                                                                     
   End of intervention            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.107                                                         N/A                                                                                                                       
   1st month follow-up            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.002^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     0.877                                                         N/A                                                         
   2nd month follow-up            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.005^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     0.261                                                       N/A
  Morning pain (VAS score)                                                                                                                                                                                                                                                              
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   N/A                                                                                                                                                                                     
   End of intervention            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.028^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                                                                       
   1st month follow-up            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.074                                                         N/A                                                         
   2nd month follow-up            \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   0.002^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^   N/A
  Cadence (step/min)                                                                                                                                                                                                                                                                    
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   1.000                                                         N/A                                                                                                                                                                                     
   End of intervention            1.000                                                         0.731                                                         N/A                                                                                                                       
   1st month follow-up            1.000                                                         0.052                                                         1.000                                                         N/A                                                         
   2nd month follow-up            0.296                                                         0.031^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     0.759                                                         1.000                                                       N/A
  Stride length (m)                                                                                                                                                                                                                                                                     
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   0.776                                                         N/A                                                                                                                                                                                     
   End of intervention            0.747                                                         1.000                                                         N/A                                                                                                                       
   1st month follow-up            0.768                                                         1.000                                                         1.000                                                         N/A                                                         
   2nd month follow-up            0.856                                                         1.000                                                         1.000                                                         1.000                                                       N/A
  Stride time (s)                                                                                                                                                                                                                                                                       
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   1.000                                                         N/A                                                                                                                                                                                     
   End of intervention            1.000                                                         0.215                                                         N/A                                                                                                                       
   1st month follow-up            0.749                                                         0.018^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         N/A                                                         
   2nd month follow-up            0.255                                                         0.020^[\*](#tfn6-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         1.000                                                       N/A
  Total double support (%)                                                                                                                                                                                                                                                              
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   1.000                                                         N/A                                                                                                                                                                                     
   End of intervention            1.000                                                         1.000                                                         N/A                                                                                                                       
   1st month follow-up            1.000                                                         1.000                                                         1.000                                                         N/A                                                         
   2nd month follow-up            0.928                                                         1.000                                                         1.000                                                         0.785                                                       N/A
  Gait speed (m/s)                                                                                                                                                                                                                                                                      
   Baseline                       N/A                                                                                                                                                                                                                                                   
   Intermediate of intervention   1.000                                                         N/A                                                                                                                                                                                     
   End of intervention            1.000                                                         1.000                                                         N/A                                                                                                                       
   1st month follow-up            1.000                                                         1.000                                                         1.000                                                         N/A                                                         
   2nd month follow-up            0.928                                                         1.000                                                         1.000                                                         0.785                                                       N/A

VAS, VAS, visual analogue scale (10 cm); N/A, not assessment.

p\<0.05.

###### 

Pairwise comparison for the stretching group (p-value)

  Parameter                       Baseline                                                      Intermediate of intervention                                  End of intervention                                         1st month follow-up   2nd month follow-up
  ------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- --------------------- ---------------------
  Worst pain (VAS score)                                                                                                                                                                                                                        
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.002^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                                                                                             
   End of intervention            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.095                                                         N/A                                                                               
   1st month follow-up            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.004^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     0.434                                                       N/A                   
   2nd month follow-up            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.005^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.246                 N/A
  Morning pain (VAS score)                                                                                                                                                                                                                      
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.011^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                                                                                             
   End of intervention            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                               
   1st month follow-up            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.043^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   N/A                   
   2nd month follow-up            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.016^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.569                 N/A
  Cadence (step/min)                                                                                                                                                                                                                            
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.049                                                         N/A                                                                                                                                             
   End of intervention            0.287                                                         1.000                                                         N/A                                                                               
   1st month follow-up            0.012^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         1.000                                                       N/A                   
   2nd month follow-up            0.045^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         0.935                                                       1.000                 N/A
  Stride length (m)                                                                                                                                                                                                                             
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.047^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                                                                                             
   End of intervention            0.126                                                         1.000                                                         N/A                                                                               
   1st month follow-up            0.002^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         0.433                                                       N/A                   
   2nd month follow-up            0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     0.136                                                         0.032                                                       0.746                 N/A
  Stride time (s)                                                                                                                                                                                                                               
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.106                                                         N/A                                                                                                                                             
   End of intervention            0.384                                                         1.000                                                         N/A                                                                               
   1st month follow-up            0.008^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         1.000                                                       N/A                   
   2nd month follow-up            0.043^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     0.757                                                         0.540                                                       1.000                 N/A
  Total double support (%)                                                                                                                                                                                                                      
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.258                                                         N/A                                                                                                                                             
   End of intervention            1.000                                                         1.000                                                         N/A                                                                               
   1st month follow-up            1.000                                                         1..000                                                        1.000                                                       N/A                   
   2nd month follow-up            0.030^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         0.629                                                       0.730                 N/A
  Gait speed (m/s)                                                                                                                                                                                                                              
   Baseline                       N/A                                                                                                                                                                                                           
   Intermediate of intervention   0.010^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     N/A                                                                                                                                             
   End of intervention            0.056                                                         1.000                                                         N/A                                                                               
   1st month follow-up            0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^     1.000                                                         0.279                                                       N/A                   
   2nd month follow-up            \<0.001^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.075                                                         0.003^[\*](#tfn7-arm-2019-43-6-662){ref-type="table-fn"}^   0.7002                N/A

VAS, VAS, visual analogue scale (10 cm); N/A, not assessment.

p\<0.05.
